Can Insmed (INSM) Still Look Reasonable After Raised Sales Guidance?

Insmed stock has delivered an extremely strong multi year gain, yet current valuation checks flag a mix of signals rather than a clear bargain or clear overpricing.

• Over the past 3 years, Insmed has returned about 3.6x, which puts pressure on today’s price to be backed by durable cash flow and product traction.
• The commercial momentum around BRINSUPRI and progress across the respiratory pipeline can support a richer multiple, while execution risk on those same products may weigh on what investors are willing to pay.
• On Simply Wall St’s broader checklist, Insmed’s value score is 3 out of 6, which points to a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether Insmed’s current share price still offers an appealing entry point once those expectations and risks are factored in.

Surf our screener containing 17 high quality undiscovered gems that, like Insmed, already have meaningful traction yet still sit off most investors’ radar.

Has Insmed Run Too Far on Sales?

P/S is a useful lens for Insmed because the company is still loss making and investors are effectively paying for revenue traction rather than current profits.

On this metric, Insmed trades on a P/S of about 24.0x, which is well above the biotech industry average of 13.2x and also ahead of the peer group on roughly 8.2x. The fair P/S ratio implied by Simply Wall St’s model is 18.4x. This suggests the current valuation sits materially higher than what that framework would expect once growth, risk and size are factored in. Despite the recent BRINSUPRI driven revenue surge and raised 2026 sales guidance, the market is still assigning a premium price tag relative to both sector norms and this tailored benchmark.

On the P/S multiple, Insmed stock appears overvalued compared with both its sector and the modelled fair ratio.

See what the numbers say about this price — find out in our valuation breakdown.

The Insmed Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Insmed pick up where that valuation puzzle leaves off by spelling out which expectations around Insmed's potential growth, profitability and earnings would need to play out for the share price to look meaningfully higher or lower than today. Each scenario ties a fair value estimate to a specific set of potential catalysts and risks so you can track over time which version of Insmed's story appears to be gaining traction, and they sit on the stock's Community page.

One of the top community narratives on Insmed: 37% undervalued

"The anticipated U.S. launch of brensocatib in bronchiectasis in the third quarter of 2025 is a major catalyst, expected to significantly increase revenue once it hits the market and starts generating sales late in Q3..."

Read one of the top narratives on Insmed

Do you think there's more to the story for Insmed? Head over to our Community to see what others are saying!

The Bottom Line

Insmed now trades on a richer P/S tag that screens as overvalued relative to its biotech peers and the tailored fair multiple. That premium places a lot of weight on the durability of BRINSUPRI momentum and the broader respiratory portfolio turning into meaningful, recurring revenue. For bulls, the case hinges on those pipelines converting into enough sales to make today’s high revenue multiple feel justified over time. For skeptics, the key question is whether the current price already bakes in most of that upside, leaving more room for execution risk than for easy upside re rating.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com